Las Vegas, NV -- (SBWIRE) -- 09/21/2013 -- PennyStockEarnings Team record for picking gainers is one of the best in the business, and our followers continue to make substantial profits – even in bear markets. Our Team includes top analysts and use level II screeners to get you the information you need to make intelligent decisions for trading penny stocks. Our Today’s Focus is On: Sequenom, Inc. (NASDAQ:SQNM), Accuray Incorporated (NASDAQ:ARAY), Dyax Corp. (NASDAQ:DYAX), InterMune Inc (NASDAQ:ITMN)
Sequenom, Inc. (NASDAQ:SQNM) jumped +0.35% and closed at $2.83 in the last trading session with the overall traded volume of 2.11 million shares, less versus the average volume of 2.36 million shares. Its 52 weeks high price was $5.36 and suffered lowest price of $2.75 in the same period.
It has market cap of $326.48 million while its total outstanding shares are 115.36 million. Its stock’s 3 months performance stands at -31.14%. Sequenom, Inc., a life sciences company, provides genetic analysis solutions in the United States and internationally. It operates through two segments, Molecular Diagnostics and Genetic Analysis.
For How Long SQNM’s Gloss will Attract Investors? Find out via this report
Accuray Incorporated (NASDAQ:ARAY) surged +3.94% with the closing price of $7.12. The overall volume in the last trading session was 2.04 million shares. Its fifty two week range was $3.76-$7.44. The total market capitalization remained $531.90 million.
The stock gained +12.84% in this year and reported the increase of +3.64% in the last 5 days. In its share capital, the company has 74.71 million outstanding shares. Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body.
What was the Moving Force behind ARAY On Bullish Run? Read This Research Report
Dyax Corp. (NASDAQ:DYAX) increased +6.48% to close at $5.84 in the last trading session and its total traded volume was 1.93 million shares, beating the average volume of 686,287. The company has market cap of $638.50 million.
The stock has positive year-to-date performance of +68.16% while its quarterly performance remained +81.21%. Dyax Corp., a biopharmaceutical company, engages in the identification, development, and commercialization of treatments for plasma kallikrein-mediated (PKM) angioedemas.
Why Should Investors Buy DYAX After The Recent Gain? Just Go Here and Find Out
InterMune Inc (NASDAQ:ITMN) declined -1.95% to closed at $15.09 and its overall volume in the last trading session was 2.46 million shares, beating the average volume of 811,256. It has market cap of $1.24 billion while its total outstanding shares are 81.95 million.
The stock gained +58.34% in this year and reported the loss of -1.05% in the last 5 days. Its 3 months performance stands at +59.77%. InterMune, Inc., a biotechnology company, engages in the research, development, and commercialization of therapies in pulmonology and orphan fibrotic diseases.
Has ITMN Found The Bottom And Ready To Gain Momentum? Find Out Here
PennyStockEarnings.com is keen to discover penny stocks with the potential to make short and long-term gains.
PSE Team record for picking gainers is one of the best in the business, and our followers continue to make substantial profits – even in bear markets. Our Team includes top analysts and use level II screeners to get you the information you need to make intelligent decisions for trading penny stocks.
PLEASE NOTE WELL: The employees of PennyStockEarnings.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockEarnings.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockEarnings.com is not offering securities for sale. Neither PennyStockEarnings.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockEarnings.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockEarnings.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer Here: http://www.pennystockearnings.com/disclaimer/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)